| Autor: |
Pinato, DJ, Kythreotou, A, Mauri, FA, Suardi, E, Allara, E, Shiner, RJ, Akarca, AU, Trivedi, P, Gupta, N, Dalla Pria, A, Marafioti, T, Oliveri, P, Newsom-Davis, T, Bower, M |
| Předmět: |
|
| Popis: |
Dear Editor, In the combined anti-retroviral therapy (cART) era, non-small cell lung cancer (NSCLC) is a highly incident cause of morbidity and mortality in people living with HIV (PLHIV)[1]. The immune-pathogenesis of NSCLC and HIV infection both rely on programmed-death 1 (PD-1) receptor-ligand interaction as a mechanism to induce T-cell exhaustion. To date, PLHIV have been excluded from clinical trials of immune-checkpoint inhibitors (ICPI), on the presumption that anti-tumour immunity might be compromised by HIV infection. To verify this, we evaluated the clinico-pathologic significance of PD-ligands expression in a consecutive series of 221 archival NSCLC samples, 24 of which were HIV-associated (Table S1). |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
